Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
Healthcare
$2.34 -4.34%
-$0.11 today
- Market cap
- $441.63M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
52W Low $0.29High $3.11
Volume 1.77M
Average 3.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$38.33M
FY 2025 · Annual
Investing Cash Flow
-$49.85M
FY 2025 · Annual
Financing Cash Flow
$75.21M
FY 2025 · Annual
+11991.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$17.4M
+ D&A$273.0K
+ Stock-Based Comp$4.8M
+ Deferred Tax$0
- Working Capital-$4.1M
- Other Non-Cash-$21.9M
= Operating Cash Flow-$38.3M
- Capex$0
= Free Cash Flow-$38.3M
Analysis
FY2025 free cash flow is -$38.3M. FCF conversion is 220.1% of net income. Operating cash flow was -$38.3M, with capex of $0. The largest bridge item is Other Non-Cash at -$21.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| S-3 | S-3 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does OVID generate free cash flow?
Ovid Therapeutics Inc. (OVID) generated -$38.33M of free cash flow in fiscal 2025.
How much operating cash flow does OVID produce?
Operating cash flow was -$38.33M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.